Compare GTN & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTN | SPRY |
|---|---|---|
| Founded | 1897 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.5M | 473.4M |
| IPO Year | 1996 | 2020 |
| Metric | GTN | SPRY |
|---|---|---|
| Price | $4.61 | $4.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $8.50 | ★ $40.00 |
| AVG Volume (30 Days) | 804.3K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,095,000,000.00 | $84,278,000.00 |
| Revenue This Year | $13.89 | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.55 | $4.07 |
| 52 Week High | $6.44 | $13.15 |
| Indicator | GTN | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 36.03 |
| Support Level | $4.21 | N/A |
| Resistance Level | $4.70 | $8.61 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 28.26 | 22.80 |
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.